Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long Term, Single-arm, Open-label Extension Study of Protocol AC-055-305 to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome

Next Previous
X
Search
Trial Profile

Long Term, Single-arm, Open-label Extension Study of Protocol AC-055-305 to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Macitentan (Primary)
  • Indications Eisenmenger complex
  • Focus Therapeutic Use
  • Acronyms MAESTRO-OL
  • Sponsors Actelion Pharmaceuticals

    • Most Recent Events

    • 13 Jan 2022 This trial has been completed in Romania, according to European Clinical Trials Database.
    • 05 Oct 2021 This trial has been completed in Spain, according to European Clinical Trials Database. (2018-01-12)
    • 17 Aug 2018 Status changed to discontinued as the parent study AC-055-305/MAESTRO (NCT01743001) did not meet its primary endpoint, the sponsor decided to prematurely terminate this open-label study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top